Expression TGM2 and BNIP3 have prognostic significance in laryngeal cancer patients receiving surgery and postoperative radiotherapy: A retrospective study

Journal of Translational Medicine

Wei-Han Hu²  Qiu-Li Li⁴  Wen-Kuan Chen⁴  Rui Sun²  Xiu-Yu Cai²  Nan Ge²  Li-Bing Guo³  Hui Lin²  Huan-Xin Lin²  Ting Jin¹ 

[1] Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, People's Republic of China;Department of Radiation Oncology, Sun Yat -sen University Cancer center, Guangzhou, Guangdong 510060, People's Republic of China;Department of Oncology, Guangdong Second Provincial People's Hospital, Guangzhou, Guangdong 510060, People's Republic of China;Department of Head and Neck Surgery, Sun Yat -sen University Cancer Center, Guangzhou, Guangdong 510060, People's Republic of China

关键词: Prognosis;    Laryngeal cancer;    Postoperative radiotherapy;    BNIP3;    TGM2;   

Others  :  1206017
DOI  :  10.1186/1479-5876-10-64

 received in 2011-10-10, accepted in 2012-03-30,  发布年份 2012

【 摘 要 】

Background

This study was designed to determine the pattern and correlation between expression of the HIF-1α transcriptional targets TGM2 and BNIP3 in laryngeal cancer, and investigate the association of BNIP3 and TGM2 with clinical outcome in laryngeal squamous cell carcinoma (SCC) patients receiving postoperative radiotherapy.

Methods

Immunostaining with antibodies specific to BNIP3 and TGM2 was performed in formalin-fixed, paraffin-embedded specimens from 148 laryngeal SCC patients. BNIP3 and TGM2 expression was scored as high or low, based on the number of tumor cells stained and the staining intensity. All patients received postoperative radiotherapy. Patient follow up and clinicopathological data were compared using the Chi-squared test, univariate and multivariate analyses, and survival curves were generated using the Kaplan-Meier method and log-rank test.

Results

The 3, 5 and 10-year overall survival rates (OS) for all patients were 77.7%, 71.6%, 56.4%, respectively. Primary tumor site, T stage, overall stage, lymph-node metastasis, BNIP3 expression and TGM2 expression were significant prognostic factors for OS in univariate analysis. Negative cervical lymph nodes, high BNIP3 expression and low TGM2 expression were independent prognostic factors of improved OS in multivariate analysis. BNIP3 expression correlates with TGM2 expression in laryngeal SCC (P = 0.012).

Conclusions

This study indicates that lymph-node metastasis, BNIP3 expression and TGM2 expression are independent prognostic factors in laryngeal SCC patients receiving postoperative radiotherapy. Further studies are required to investigate how BNIP3 and/or TGM2 influence the prognosis of laryngeal SCC patients treated with postoperative radiotherapy, and to determine how TGM2 and BNIP3 expression are regulated.

【 授权许可】

   
2012 Jin et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics. CA Cancer J Clin 2008, 58:71-96.
• [2]Bruick RK: Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci USA 2000, 97:9082-9087.
• [3]Guo K, Searfoss G, Krolikowski D, Pagnoni M, Franks C, Clark K, Yu KT, Jaye M, Ivashchenko Y: Hypoxia induces the expression of the pro-apoptotic gene BNIP3. Cell Death Differ 2001, 8:367-376.
• [4]Regula KM, Ens K, Kirshenbaum LA: Inducible expression of BNIP3 provokes mitochondrial defects and hypoxia-mediated cell death of ventricular myocytes. Circ Res 2002, 91:226-231.
• [5]Okami J, Simeone DM, Logsdon CD: Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer. Cancer Res 2004, 64:5338-5346.
• [6]Erkan M, Kleeff J, Esposito I, Giese T, Ketterer K, Büchler MW, Giese NA, Friess H: Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 2005, 24:4421-4432.
• [7]Tang H, Liu YJ, Liu M, Li X: Establishment and gene analysis of an oxaliplatin-resistant colon cancer cell line THC8307/L-OHP. Anticancer Drugs 2007, 18:633-639.
• [8]Folk JE: Transglutaminases. Annu Rev Biochem 1980, 49:517-531.
• [9]Jang GY, Jeon JH, Cho SY, Shin DM, Kim CW, Jeong EM, Bae HC, Kim TW, Lee SH, Choi Y, Lee DS, Park SC, Kim IG: Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells. Oncogene 2010, 29:356-367.
• [10]Mehta K, Fok J, Miller FR, Koul D, Sahin AA: Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 2004, 10:8068-8076.
• [11]Lee J, Kim YS, Choi DH, Bang MS, Han TR, Joh TH, Kim SY: Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia. J Biol Chem 2004, 279:53725-53735.
• [12]Thompson L: World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Ear Nose Throat J 2006, 85:74.
• [13]Boddy JL, Fox SB, Han C, Campo L, Turley H, Kanga S, Malone PR, Harris AL: The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 2005, 11:7658-7663.
• [14]Bastit L, Blot E, Debourdeau P, Menard J, Bastit P, Le Fur R: Influence of the delay of adjuvant postoperative radiation therapy on relapse and survival in oropharyngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys 2001, 49(1):139-146.
• [15]Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB: Recurrence at the primary site in head and neck cancer and the significance of neck node metastases as a prognostic factor. Cancer 1993, 73(1):187-190.
• [16]Leibel SA, Scott CB, Mohiuddin M, Marcial VA, Coia LR, Davis LW, Fuks Z: The effect of local-regional control on distant metastatic dissemination in carcinoma of the head and neck: results of an analysis from the RTOG head and neck database. Int J Radiat Oncol Biol Phys 1991, 21(3):549-556.
• [17]Richard JM, Sancho-Garnier H, Micheau C, Saravane D, Cachin Y: Prognostic factors in cervical lymph node metastasis in upper respiratory and digestive tract carcinomas: study of 1713 cases during a 15-year period. Laryngoscope 1987, 97(1):97-101.
• [18]Stell PM: Prognosis in laryngeal carcinoma: tumor factors. Clin Otolaryngol 1990, 15(1):69-81.
• [19]Hoffstetter S, Malissard L, N'Guyen TD, Panis X, Jung GM, Bachaud JM, Prevost B, Quint R, Chaplain G, Eschwège F, Rambert P, Fleury-Touzeau F: Results of postoperative cervical node irradiation in carcinoma of the pharyngo-larynx. A study of the cooperative group of radiotherapist. Bull Cancer Radiother 1996, 83(2):86-89.
• [20]van den Bogaert W, Ostyn F, van der Schueren E: The different clinical presentation, behaviour and prognosis of carcinomas originating in the epilarynx and lower supraglottis. Radiother Oncol 1983, 1(2):117-131.
• [21]Wall TJ, Peters LJ, Brown BW, Oswald MJ, Milas L: Relationship between lymph nodal status and primary tumor control probability in tumors of the supraglottic larynx. Int J Radiat Oncol Biol Phys 1985, 11(11):1895-1902.
• [22]Kramer S, Gelber RD, Snow JB, Marcial VA, Lowry LD, Davis LW, Chandler R: Combined radiation therapy and surgery in the management of advanced head and neck cancer: final report of the study 73-03 of the Radiation Therapy Oncology Group. Head Neck Surg 1987, 10(1):19-30.
• [23]Nguyen TD, Malissard L, Théobald S, Eschwège F, Panis X, Bachaud JM, Rambert P, Chaplain G, Quint R: Advanced carcinoma of the larynx: results of surgery and radiotherapy without induction chemotherapy (1980-1985): a multivariate analysis. Int J Radiat Oncol Biol Phys 1996, 5(5):1013-1018.
• [24]Wolf GT, Hong WK, Fisher SG: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with laryngeal cancer. N Engl J Med 1991, 324(24):1685-1690.
• [25]Leibel SA, Fuks Z: The impact of local tumor control on the outcome of human cancer. In Current topics in clinical radiobiology of tumors. Edited by Beck-B ornholdt HP. Berlin: Springer-Ve rlag; 1993:113-127.
• [26]Mangala LS, Fok JY, Zorrilla-Calancha IR, Verma A, Mehta K: Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 2007, 26:2459-2470.
• [27]Mann AP, Verma A, Sethi G, Manavathi B, Wang H, Fok JY, Kunnumakkara AB, Kumar R, Aggarwal BB, Mehta K: Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res 2006, 66:8788-8795.
• [28]Dardik R, Inbal A: Complex formation between tissue transglutaminase II (tTG) and vascular endothelial growth factor receptor 2 (VEGFR-2): proposed mechanism for modulation of endothelial cell response to VEGF. Exp Cell Res 2006, 312:2973-2982.
• [29]Kim DS, Park KS, Jeong KC, Lee BI, Lee CH, Kim SY: Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition. Cancer Lett 2009, 273:243-249.
• [30]Barnes RN, Bungay PJ, Elliott BM, Walton PL, Griffin M: Alterations in the distribution and activity of transglutaminase during tumour growth and metastasis. Carcinogenesis 1985, 6:459-463.
• [31]Fesus L, Thomazy V, Falus A: Induction and activation of tissue transglutaminase during programmed cell death. FEBS Lett 1987, 224:104-108.
• [32]Yuan L, Behdad A, Siegel M, Khosla C, Higashikubo R, Rich KM: Tissue transgluaminase 2 expression in meningiomas. J Neurooncol 2008, 90:125-132.
• [33]Mian S: el Alaoui S, Lawry J, Gentile V, Davies PJ, Griffin M: The importance of the GTP-binding protein tissue transglutaminase in the regulation of cell cycle progression. FEBS Lett 1995, 370:27-31.
• [34]Kothari S, Cizeau J, McMillan-Ward E, Israels SJ, Bailes M, Ens K, Kirshenbaum LA, Gibson SB: BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene 2003, 22:4734-4744.
• [35]Kennedy AS, Harrison GH, Mansfield CM, Zhou XJ, Xu JF, Balcer-Kubiczek EK: Survival of colorectal cancer cell lines treated with paclitaxel, radiation, and 5-FU: effect of TP53 or hMLH1 deficiency. Int J Cancer 2000, 90:175-185.
• [36]Baetz D, Regula KM, Ens K, Shaw J, Kothari S, Yurkova N, Kirshenbaum LA: Nuclear factor-kappaB-mediated cell survival involves transcriptional silencing of the mitochondrial death gene BNIP3 in ventricular myocytes. Circulation 2005, 112:3777-3785.